Skip to main
BSX

Boston Scientific (BSX) Stock Forecast & Price Target

Boston Scientific (BSX) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 48%
Buy 52%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Boston Scientific is implementing cost reduction efforts and diversifying their portfolio through new product launches and clinical trials, which could lead to strong earnings growth and potential for future growth opportunities. Additionally, their commitment to sustainability and addressing healthcare disparities, as well as their strategic focus on "Prevent, Provide, and Prepare" suggest a positive long-term outlook. The company's recent earnings beat and efforts to strengthen their leadership and portfolio through M&A and share repurchases further support a positive outlook for the company.

Bears say

Boston Scientific is continuing to struggle with slow growth in its MedSurg segment, which was only partially offset by strong Neuromodulation sales. The company's recent guidance cut highlights the challenges they face in their Urology business and issues with the supply chain. Despite their growth strategy and potential for M&A, it may take some time for this company to see significant improvements in their financials.

Boston Scientific (BSX) has been analyzed by 21 analysts, with a consensus rating of Buy. 48% of analysts recommend a Strong Buy, 52% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Boston Scientific (BSX) Forecast

Analysts have given Boston Scientific (BSX) a Buy based on their latest research and market trends.

According to 21 analysts, Boston Scientific (BSX) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $91.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $91.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Boston Scientific (BSX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.